Matthew R. Bryan

Matthew R. Bryan

Auto-generated profile, based on publicly available information

Matthew R. Bryan

Harvard Medical School, 25 Shattuck St, Boston, MA, 02115, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2024 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
ASAndrew Schoenfeld
Andrew Schoenfeld
ZCZara Cooper
Zara Cooper
ABAmanda Banaag
Amanda Banaag
JGJonathan Gong
Jonathan Gong
MBMatthew R. Bryan
Matthew R. Bryan
TKTracey P. Koehlmoos
Tracey P. Koehlmoos
Over the last decade, numerous efforts have been made to combat the opioid crisis globally. The impact of these strategies has not been adequately measured and may differ across populations depending on baseline risk. We compared changes in long-term prescription opioid use following surgery within a national US cohort, between 2017 and 2022. We used TRICARE claims data to identify individuals undergoing one of 14 representative surgical procedures. The rate of post-operative long-term prescription opioid use during 2020-22 was compared to 2017-19. We used modified Poisson regression analyses to adjust for confounding. We performed secondary analyses that accounted for interactions between the time period and race, pre-operative opioid use, surgical care setting and our proxy for socioeconomic status. Our data derived from TRICARE claims. We included 410,326 surgical events. Across both time periods, there were 213,212 females (52%), with a median age of 53 (IQR 22) and 207,188 individuals of White race (50%). The median co-morbidity index was 0 (IQR = 0). The rate of long-term post-operative opioid use was 11% in 2017-19, which reduced to 6% in 2020-22 (risk ratio [RR] 0.51; 95% CI 0.50, 0.52). Reductions were appreciated across all census divisions in the US and across all racial minorities, those of lower socioeconomic background and pre-operative chronic opioid users. Following multivariable analysis, there was a significant reduction in long-term prescription opioid use (RR 0.61; 95% CI 0.60, 0.63) after surgery in 2020-22 as compared to 2017-19. This investigation represents one of the largest and most comprehensive longitudinal assessments of opioid use following surgery. We found clinically relevant reductions in post-operative prescription opioid use in 2020-22 as compared to 2017-19. Given the representative nature of the study cohort, we believe these results are reflective of national trends. U.S. Department of Defense, Defense Health Agency (award # HU00012120089).

1 July 2025 in JBJS Open Access
Verified
Journal Article
Open access
MCMark P. Cote
Mark P. Cote
KHKaitlyn E. Holly
Kaitlyn E. Holly
RSRoman J. Schoenfeld
Roman J. Schoenfeld
MBMatthew R. Bryan
Matthew R. Bryan
MHMalina O. Hatton
Malina O. Hatton
ASAndrew Schoenfeld
Andrew Schoenfeld
Background: It is unclear whether the current North Atlantic Treaty Organization (NATO) trauma system will be effective in the setting of Large-Scale Combat Operations (LSCO). We sought to model the efficacy of the NATO trauma system in the setting of LSCO. We also intended to model novel scenarios that could better adapt the current system to LSCO. Methods: We developed a discrete-event simulation model for patients with combat musculoskeletal injuries treated within the standard NATO system. The primary outcome of the model was survival. The model’s health states were characterized as stable, hypovolemia, sepsis, shock, or death. The model simulated combat intensity by increasing the number of casualties up to 192 casualties per 24 hours. We explored how an augmented system (FC) and Field Hospital (FH) moved closer to the battlefront would change performance. Results: Mortality rates rose precipitously from a 10% baseline to 61% at 12 casualties per 24 hours in the base model. This performance was not significantly different from that of the FC model at any casualty rate. Successful evacuation of casualties was significantly more for the FH model versus the base model at 12 casualties/24 hours (47.5% vs. 39%; p = 0.046), 48 casualties/24 hours (45.5% vs. 33%; p = 0.008), and 192 casualties/24 hours (25% vs. 15.5%; p = 0.02). Conclusions: The current NATO model experiences high rates of mortality in LSCO. The most effective modification entails situating Field Hospitals within one-hour of ground transport from the battlefront. Level of Evidence: Level III. See Instructions for Authors for a complete description of levels of evidence.

27 July 2024 in Arthroscopy Techniques
Verified
Journal Article
Open access
MBMatthew R. Bryan
Matthew R. Bryan
AWAlex E. White
Alex E. White
PIPaul M. Inclan
Paul M. Inclan
SOStephen J. O'BRien
Stephen J. O'BRien
STSamuel A. Taylor
Samuel A. Taylor
Biceps‐labrum complex (BLC) disease is a well‐established pain generator in the shoulder. Despite its ubiquity, BLC disease continues to pose a diagnostic challenge for orthopaedic surgeons. The use of magnetic resonance imaging and glenohumeral arthroscopy in the diagnosis of BLC disease has proven to be inadequate when performed independently. As a result, physical examination remains a critical component in the evaluation of BLC disease. The purpose is to provide a comprehensive compendium of physical examination maneuvers in the evaluation of BLC disease. Technique Video: video See video under supplementary data.

28 March 2025 in Oxford Medical Case Reports
Verified
Journal Article
Open access
GBGordon P Bensen
Gordon P Bensen
MBMatthew R Bryan
Matthew R Bryan
ENEsther Nishimwe
Esther Nishimwe
BNBao Sean Nguyen
Bao Sean Nguyen
KCKenechukwu Chudy-Onwugaje
Kenechukwu Chudy-Onwugaje
We describe a case of oral contraceptive pill (OCP)-induced esophagitis in a 43-year-old Rwandan woman. She presented with epigastric and retrosternal pain and reported daily use of a combined OCP containing ethinyl estradiol and levonorgestrel. Upper endoscopy revealed a solitary, clean-based esophageal ulcer. Histopathologic evaluation excluded infectious causes, and she improved with proton pump inhibitor therapy and modification of pill consumption habits. This is the first reported case of OCP-induced esophagitis on the African continent and the fifth case overall, and it highlights the importance of awareness of this rare gastrointestinal adverse effect of a commonly used class of drugs, particularly in an area of the world that is promoting the increased uptake of female contraception as a tool for family planning.

19 November 2024 in Arthroscopy Techniques
Verified
Journal Article
Open access
AWAlexander E. White
Alexander E. White
TUTyler J. Uppstrom
Tyler J. Uppstrom
NPNicolas Pascual‐Leone
Nicolas Pascual‐Leone
MBMatthew R. Bryan
Matthew R. Bryan
STSamuel A. Taylor
Samuel A. Taylor
Quadriceps tendon tears are a common injury that are often treated in the chronic setting. Significant tendon retraction and scar tissue formation in the chronic setting leads to inferior outcomes after surgical treatment for these injuries compared to those treated in the acute setting. Although numerous treatment strategies for chronic quadriceps tendon insufficiency have been described, there remains no clear consensus on the standard of treatment. This technical note describes our preferred surgical approach for select cases of chronic quadriceps insufficiency with the use of a pedicled quadriceps tendon autograft in a quadriceps turndown technique. Technique Video: video See video under supplementary data.

18 April 2025 in The Lancet Regional Health - Americas
Verified
Journal Article
Open access
ASAndrew Schoenfeld
Andrew Schoenfeld
KHKaitlyn E. Holly
Kaitlyn E. Holly
MBMatthew R. Bryan
Matthew R. Bryan
MHMalina O. Hatton
Malina O. Hatton
MWMatthew Wien
Matthew Wien
TKTracey P. Koehlmoos
Tracey P. Koehlmoos
Research has shown that multiple deployments may have adverse effects on active-duty servicewomen and women civilian dependents of active-duty servicemembers. There is concern that the associated stress could induce sustained prescription opioid use and substance use disorder (SUD). We sought to evaluate the incidence of sustained opioid use and SUD among servicewomen and women civilian dependents during 2006–2013, a period of increased operational intensity, compared to similar individuals in 2014–2022. We employed Military Health System claims data to identify servicewomen and dependents who were diagnosed with SUD or demonstrated sustained prescription opioid use (i.e., six months of uninterrupted use). The incidence of sustained opioid use (primary outcome) and SUD associated (secondary outcome) with 2006–2013 was compared to 2014–2022 among servicewomen and dependents. Multivariable log binomial regression was used to adjust for confounding. Ethnicity was not available in our dataset. 4,876,209 individuals were included. The average age (standard deviation [SD]) of the cohorts under study were 26.6 (SD 8.2) for active duty 2006–2013, 26.0 (SD 8.0) for active duty 2014–2022, 35.3 (SD 13.1) for dependents 2006–2013 and 33.6 (SD 12.1) for dependents 2014–2022. Compared to civilian dependents in 2014–2022, servicewomen from 2006 to 2013 demonstrated an increased risk of sustained prescription opioid use (RR 1.49, 95% CI 1.46–1.53). In 2014–2022, servicewomen had a lower risk compared to dependents (RR 0.47, 95% CI 0.45–0.49), while dependents in 2006–2013 were also at higher risk (RR 1.58, 95% CI 1.56–1.60). Servicewomen in 2006–2013 were at significantly greater risk of developing SUD (RR 1.07, 95% CI 1.06–1.08). During 2014–2022, servicewomen displayed a lower risk when compared to dependents (RR 0.80, 95% CI 0.79–0.81). Dependents in 2006–2013 showed a higher risk (RR 1.24, 95% CI 1.24–1.25). We found significant increases in the risks of sustained opioid use and SUD among servicewomen and civilian dependents during a period of increased operational intensity (2006–2013). We believe these findings reflect the deleterious effects of emotional stress, insufficient support structures, and military sexual trauma. 10.13039/100005712 U.S. Department of Defense, Defense Health Agency (#HU00012320021).